Novo Targets More Than DKK150B In Pipeline Sales In 2035
Aims To Launch More Than 5 Multi Blockbusters By 2030 Targets Greater Than/Equal To 5 Phase 3 Programs In Obesity, Diabetes By 2030 Aims To Deliver 2026-30 Rev CAGR In Line With Industry Peers
Story updates
08:08:04 AM UTC
SquawkNews
Sept 21 (Reuters) — Novo Nordisk A/S: Highlights To Be Presented At Novo’s Capital Markets Day 2026 Ambition For 2030: Scale Capacity To Be Able To Serve 10x More People With Obesity On Oral Glp-1 Cmd Upade To Cover: Aim Deliver 2026-30 Revenue Cagr In Line With Industry Peers Cmd Update To Cover: Aim To Maintain Broadly Stable Operating Margin Source text:... Further company coverage: NOVOb.CO (Gdansk Newsroom) ((gdansk.newsroom@thomsonreuters.com; +48 58 772 0920;)